David Church
Concepts (320)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle, Skeletal | 28 | 2025 | 804 | 5.260 |
Why?
| | Muscle Proteins | 13 | 2024 | 321 | 3.380 |
Why?
| | Exercise | 23 | 2025 | 547 | 2.510 |
Why?
| | Resistance Training | 15 | 2025 | 101 | 2.120 |
Why?
| | Insulin Antibodies | 3 | 2021 | 4 | 1.870 |
Why?
| | Dietary Proteins | 9 | 2024 | 252 | 1.870 |
Why?
| | Dietary Supplements | 15 | 2023 | 465 | 1.850 |
Why?
| | Autoimmune Diseases | 3 | 2021 | 86 | 1.730 |
Why?
| | Aging | 6 | 2025 | 701 | 1.660 |
Why?
| | Sarcopenia | 5 | 2025 | 98 | 1.600 |
Why?
| | Insulin | 9 | 2021 | 479 | 1.510 |
Why?
| | Amino Acids, Essential | 6 | 2024 | 133 | 1.430 |
Why?
| | Amino Acids | 5 | 2023 | 377 | 1.100 |
Why?
| | Military Personnel | 5 | 2022 | 177 | 1.050 |
Why?
| | Carnosine | 4 | 2018 | 5 | 1.000 |
Why?
| | Meals | 3 | 2024 | 63 | 0.970 |
Why?
| | Protein Biosynthesis | 5 | 2020 | 258 | 0.960 |
Why?
| | Athletic Performance | 4 | 2020 | 33 | 0.910 |
Why?
| | Diet | 8 | 2024 | 587 | 0.910 |
Why?
| | beta-Alanine | 3 | 2018 | 10 | 0.860 |
Why?
| | Feeding Behavior | 1 | 2024 | 192 | 0.810 |
Why?
| | Young Adult | 31 | 2024 | 4329 | 0.800 |
Why?
| | Cat Diseases | 3 | 2016 | 7 | 0.760 |
Why?
| | Male | 48 | 2025 | 26761 | 0.760 |
Why?
| | Humans | 68 | 2025 | 52483 | 0.760 |
Why?
| | Congenital Hyperinsulinism | 2 | 2018 | 4 | 0.740 |
Why?
| | Muscle Contraction | 2 | 2019 | 117 | 0.730 |
Why?
| | Hyperinsulinism | 1 | 2021 | 30 | 0.720 |
Why?
| | Hypoglycemia | 1 | 2021 | 59 | 0.690 |
Why?
| | Chromatography, Gel | 2 | 2018 | 40 | 0.680 |
Why?
| | Anabolic Agents | 3 | 2025 | 44 | 0.680 |
Why?
| | Endometrial Neoplasms | 4 | 2024 | 144 | 0.680 |
Why?
| | Peptides | 1 | 2021 | 223 | 0.670 |
Why?
| | Caloric Restriction | 3 | 2025 | 38 | 0.640 |
Why?
| | Insulin-Like Growth Factor I | 3 | 2016 | 139 | 0.640 |
Why?
| | Muscle Strength | 5 | 2025 | 130 | 0.640 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 1884 | 0.630 |
Why?
| | Military Medicine | 1 | 2019 | 24 | 0.630 |
Why?
| | Stress, Physiological | 2 | 2019 | 183 | 0.610 |
Why?
| | Muscular Atrophy | 1 | 2019 | 71 | 0.610 |
Why?
| | Liver | 2 | 2024 | 1156 | 0.600 |
Why?
| | Adult | 31 | 2024 | 14161 | 0.600 |
Why?
| | Occupational Diseases | 1 | 2019 | 85 | 0.590 |
Why?
| | Leucine | 3 | 2023 | 114 | 0.580 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2021 | 266 | 0.550 |
Why?
| | Polyphenols | 4 | 2018 | 38 | 0.550 |
Why?
| | Cross-Over Studies | 10 | 2022 | 238 | 0.540 |
Why?
| | Chemical Precipitation | 1 | 2016 | 4 | 0.530 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 80 | 0.530 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2016 | 12 | 0.530 |
Why?
| | Immunoassay | 1 | 2016 | 23 | 0.530 |
Why?
| | Triterpenes | 1 | 2016 | 11 | 0.520 |
Why?
| | Multiprotein Complexes | 1 | 2016 | 25 | 0.510 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 47 | 0.510 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2016 | 28 | 0.510 |
Why?
| | Fatigue | 3 | 2025 | 125 | 0.490 |
Why?
| | Female | 27 | 2024 | 28171 | 0.490 |
Why?
| | Coffee | 1 | 2015 | 11 | 0.490 |
Why?
| | Double-Blind Method | 10 | 2021 | 713 | 0.480 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 334 | 0.480 |
Why?
| | Reaction Time | 1 | 2015 | 209 | 0.460 |
Why?
| | Nandrolone | 2 | 2025 | 6 | 0.460 |
Why?
| | Polymorphism, Genetic | 2 | 2014 | 185 | 0.450 |
Why?
| | Monocytes | 4 | 2018 | 130 | 0.430 |
Why?
| | Aged | 12 | 2025 | 10121 | 0.420 |
Why?
| | Colorectal Neoplasms | 3 | 2024 | 294 | 0.420 |
Why?
| | Muscle Fatigue | 3 | 2025 | 15 | 0.410 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2016 | 560 | 0.410 |
Why?
| | Quadriceps Muscle | 3 | 2018 | 47 | 0.410 |
Why?
| | Phenylalanine | 3 | 2022 | 132 | 0.390 |
Why?
| | Postprandial Period | 3 | 2021 | 73 | 0.380 |
Why?
| | Valerates | 3 | 2017 | 39 | 0.380 |
Why?
| | Animals | 11 | 2025 | 13505 | 0.350 |
Why?
| | Dietary Carbohydrates | 2 | 2024 | 90 | 0.350 |
Why?
| | Infant, Premature | 2 | 2024 | 333 | 0.340 |
Why?
| | Middle Aged | 11 | 2025 | 13028 | 0.340 |
Why?
| | C-Peptide | 2 | 2021 | 25 | 0.340 |
Why?
| | Blood Glucose | 3 | 2018 | 473 | 0.330 |
Why?
| | Neoadjuvant Therapy | 2 | 2024 | 125 | 0.330 |
Why?
| | Energy Metabolism | 2 | 2024 | 302 | 0.320 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2025 | 399 | 0.320 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 1222 | 0.320 |
Why?
| | Cytokines | 3 | 2017 | 623 | 0.310 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 3 | 2017 | 39 | 0.310 |
Why?
| | Polyethylene Glycols | 2 | 2021 | 90 | 0.300 |
Why?
| | Proteins | 2 | 2022 | 348 | 0.300 |
Why?
| | Paresthesia | 2 | 2018 | 8 | 0.290 |
Why?
| | Neoplasms | 2 | 2018 | 1325 | 0.290 |
Why?
| | Histidine | 2 | 2017 | 15 | 0.280 |
Why?
| | Quality of Life | 2 | 2025 | 879 | 0.280 |
Why?
| | Eating | 4 | 2022 | 159 | 0.270 |
Why?
| | Meat | 2 | 2024 | 60 | 0.270 |
Why?
| | Exercise Test | 5 | 2019 | 141 | 0.260 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2024 | 649 | 0.260 |
Why?
| | Adolescent | 10 | 2024 | 6739 | 0.250 |
Why?
| | Enteral Nutrition | 2 | 2024 | 154 | 0.250 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2025 | 4 | 0.240 |
Why?
| | Isometric Contraction | 4 | 2018 | 21 | 0.240 |
Why?
| | Niacinamide | 1 | 2025 | 23 | 0.240 |
Why?
| | Diet, Reducing | 1 | 2025 | 36 | 0.240 |
Why?
| | Sirolimus | 1 | 2025 | 65 | 0.230 |
Why?
| | Signal Transduction | 5 | 2024 | 1671 | 0.230 |
Why?
| | DNA Mismatch Repair | 1 | 2024 | 18 | 0.230 |
Why?
| | Metformin | 1 | 2025 | 76 | 0.220 |
Why?
| | Athletes | 3 | 2020 | 104 | 0.220 |
Why?
| | Cattle | 1 | 2024 | 205 | 0.220 |
Why?
| | Risk Factors | 5 | 2024 | 3889 | 0.220 |
Why?
| | Digestion | 2 | 2020 | 29 | 0.220 |
Why?
| | Androgens | 1 | 2024 | 70 | 0.210 |
Why?
| | Adipose Tissue | 1 | 2025 | 204 | 0.210 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 38 | 0.210 |
Why?
| | Random Allocation | 1 | 2024 | 285 | 0.210 |
Why?
| | Proteolysis | 2 | 2020 | 101 | 0.210 |
Why?
| | Nutritional Status | 2 | 2023 | 137 | 0.200 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 236 | 0.200 |
Why?
| | Chemokine CCL2 | 3 | 2018 | 69 | 0.200 |
Why?
| | Malnutrition | 1 | 2023 | 90 | 0.190 |
Why?
| | Cats | 3 | 2016 | 73 | 0.190 |
Why?
| | Colonic Neoplasms | 1 | 2023 | 163 | 0.190 |
Why?
| | Proinsulin | 1 | 2021 | 1 | 0.180 |
Why?
| | Body Mass Index | 4 | 2021 | 689 | 0.180 |
Why?
| | Molecular Weight | 1 | 2021 | 82 | 0.180 |
Why?
| | Dogs | 2 | 2019 | 180 | 0.180 |
Why?
| | Food Analysis | 1 | 2021 | 28 | 0.180 |
Why?
| | Myocardium | 1 | 2024 | 453 | 0.180 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 220 | 0.180 |
Why?
| | Metabolism | 1 | 2020 | 25 | 0.180 |
Why?
| | Actinidia | 1 | 2020 | 7 | 0.170 |
Why?
| | Food | 1 | 2020 | 66 | 0.170 |
Why?
| | Running | 2 | 2020 | 22 | 0.170 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 240 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2020 | 505 | 0.170 |
Why?
| | Epigenomics | 1 | 2020 | 75 | 0.170 |
Why?
| | Carbohydrate Metabolism | 1 | 2019 | 23 | 0.160 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 251 | 0.160 |
Why?
| | Receptors, CCR2 | 2 | 2016 | 13 | 0.160 |
Why?
| | Insulin Resistance | 2 | 2018 | 275 | 0.160 |
Why?
| | Physical Fitness | 2 | 2016 | 57 | 0.160 |
Why?
| | Mice | 3 | 2025 | 5949 | 0.160 |
Why?
| | Adaptation, Physiological | 1 | 2020 | 110 | 0.160 |
Why?
| | Testosterone | 4 | 2023 | 141 | 0.160 |
Why?
| | Hormones | 1 | 2019 | 59 | 0.160 |
Why?
| | Kinetics | 1 | 2020 | 626 | 0.160 |
Why?
| | Kidney | 1 | 2024 | 707 | 0.160 |
Why?
| | Prednisolone | 1 | 2019 | 56 | 0.160 |
Why?
| | Proteome | 1 | 2020 | 171 | 0.150 |
Why?
| | Occupational Health | 1 | 2019 | 66 | 0.150 |
Why?
| | Patient Compliance | 2 | 2017 | 230 | 0.150 |
Why?
| | Diazoxide | 1 | 2018 | 7 | 0.150 |
Why?
| | Alzheimer Disease | 1 | 2023 | 332 | 0.150 |
Why?
| | Football | 2 | 2016 | 75 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2019 | 102 | 0.150 |
Why?
| | Lactic Acid | 2 | 2016 | 78 | 0.150 |
Why?
| | Delayed-Action Preparations | 1 | 2018 | 55 | 0.150 |
Why?
| | Cognition | 2 | 2023 | 331 | 0.140 |
Why?
| | Martial Arts | 1 | 2017 | 1 | 0.140 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2017 | 14 | 0.140 |
Why?
| | Syndrome | 1 | 2018 | 247 | 0.140 |
Why?
| | Hand Strength | 1 | 2017 | 23 | 0.140 |
Why?
| | Glucose | 1 | 2019 | 355 | 0.140 |
Why?
| | Accidents, Traffic | 1 | 2018 | 90 | 0.140 |
Why?
| | Nutrition Assessment | 1 | 2017 | 66 | 0.140 |
Why?
| | Postural Balance | 1 | 2017 | 58 | 0.130 |
Why?
| | Supine Position | 1 | 2016 | 28 | 0.130 |
Why?
| | Glucocorticoids | 1 | 2019 | 235 | 0.130 |
Why?
| | Granulocytes | 1 | 2016 | 27 | 0.130 |
Why?
| | Energy Intake | 3 | 2024 | 174 | 0.130 |
Why?
| | Physical Education and Training | 1 | 2016 | 23 | 0.130 |
Why?
| | Work Capacity Evaluation | 1 | 2016 | 21 | 0.130 |
Why?
| | Dietary Fats | 1 | 2017 | 130 | 0.130 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2016 | 28 | 0.130 |
Why?
| | Milk Proteins | 1 | 2017 | 77 | 0.130 |
Why?
| | Methylprednisolone | 1 | 2016 | 41 | 0.130 |
Why?
| | Patient Positioning | 1 | 2016 | 32 | 0.130 |
Why?
| | Antioxidants | 1 | 2018 | 256 | 0.130 |
Why?
| | Immunosuppressive Agents | 1 | 2018 | 243 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2016 | 34 | 0.130 |
Why?
| | Hydrocortisone | 4 | 2017 | 111 | 0.130 |
Why?
| | Rest | 1 | 2016 | 60 | 0.120 |
Why?
| | Performance-Enhancing Substances | 1 | 2015 | 5 | 0.120 |
Why?
| | Clonal Evolution | 1 | 2016 | 58 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 121 | 0.120 |
Why?
| | DNA, Neoplasm | 1 | 2016 | 146 | 0.120 |
Why?
| | Plant Extracts | 1 | 2018 | 194 | 0.120 |
Why?
| | Caffeine | 1 | 2015 | 61 | 0.120 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 186 | 0.120 |
Why?
| | Mutation | 2 | 2018 | 1347 | 0.120 |
Why?
| | NF-kappa B | 1 | 2016 | 322 | 0.120 |
Why?
| | Ultrasonography | 1 | 2016 | 430 | 0.120 |
Why?
| | Body Composition | 3 | 2022 | 338 | 0.110 |
Why?
| | Esophageal Neoplasms | 1 | 2016 | 111 | 0.110 |
Why?
| | Dihydrouracil Dehydrogenase (NADP) | 1 | 2014 | 1 | 0.110 |
Why?
| | Postoperative Complications | 1 | 2021 | 1068 | 0.110 |
Why?
| | Thymidylate Synthase | 1 | 2014 | 10 | 0.110 |
Why?
| | Deoxycytidine | 1 | 2014 | 29 | 0.110 |
Why?
| | Heart Rate | 1 | 2015 | 318 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 1378 | 0.110 |
Why?
| | Fluorouracil | 1 | 2014 | 59 | 0.110 |
Why?
| | Blood Pressure | 1 | 2015 | 537 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 528 | 0.100 |
Why?
| | Myoglobin | 3 | 2017 | 25 | 0.100 |
Why?
| | Time Factors | 4 | 2021 | 2968 | 0.100 |
Why?
| | Adenocarcinoma | 1 | 2016 | 405 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 488 | 0.090 |
Why?
| | Tyrosine | 2 | 2022 | 87 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2024 | 5422 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 316 | 0.090 |
Why?
| | Oxygen Consumption | 2 | 2020 | 198 | 0.080 |
Why?
| | Macrophage-1 Antigen | 2 | 2018 | 6 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1031 | 0.070 |
Why?
| | Chemokine CX3CL1 | 2 | 2018 | 9 | 0.070 |
Why?
| | Creatine Kinase | 2 | 2017 | 29 | 0.070 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2017 | 71 | 0.070 |
Why?
| | Leg | 2 | 2017 | 120 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2020 | 467 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2024 | 2867 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 374 | 0.060 |
Why?
| | Diffusion Tensor Imaging | 2 | 2017 | 95 | 0.060 |
Why?
| | Pyridinium Compounds | 1 | 2025 | 20 | 0.060 |
Why?
| | Infant | 2 | 2024 | 3733 | 0.060 |
Why?
| | Physical Conditioning, Animal | 1 | 2025 | 59 | 0.060 |
Why?
| | Keratins | 1 | 2024 | 27 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2024 | 27 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2024 | 124 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2024 | 85 | 0.050 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2023 | 17 | 0.050 |
Why?
| | Crime | 1 | 2023 | 27 | 0.050 |
Why?
| | Micronutrients | 1 | 2023 | 17 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 483 | 0.050 |
Why?
| | Phylogeny | 1 | 2023 | 231 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2016 | 944 | 0.050 |
Why?
| | Polyesters | 1 | 2022 | 14 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2023 | 117 | 0.050 |
Why?
| | Memory, Short-Term | 1 | 2023 | 72 | 0.050 |
Why?
| | Residence Characteristics | 1 | 2023 | 159 | 0.050 |
Why?
| | Isotopes | 1 | 2022 | 25 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 1678 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 256 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2024 | 772 | 0.050 |
Why?
| | Egg Proteins | 1 | 2021 | 18 | 0.050 |
Why?
| | Food, Fortified | 1 | 2021 | 27 | 0.040 |
Why?
| | Basal Metabolism | 1 | 2020 | 33 | 0.040 |
Why?
| | Plant Proteins | 1 | 2021 | 71 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2020 | 21 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 40 | 0.040 |
Why?
| | Anaerobiosis | 1 | 2020 | 20 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2025 | 807 | 0.040 |
Why?
| | Growth Differentiation Factors | 1 | 2020 | 2 | 0.040 |
Why?
| | Puberty | 1 | 2020 | 23 | 0.040 |
Why?
| | Follistatin | 1 | 2020 | 2 | 0.040 |
Why?
| | Myostatin | 1 | 2020 | 10 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 118 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2023 | 291 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 69 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 1470 | 0.040 |
Why?
| | United States | 2 | 2024 | 5192 | 0.040 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2020 | 58 | 0.040 |
Why?
| | Alleles | 1 | 2020 | 276 | 0.040 |
Why?
| | Fruit | 1 | 2020 | 128 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2024 | 6607 | 0.040 |
Why?
| | Cohort Studies | 1 | 2023 | 1542 | 0.040 |
Why?
| | Prognosis | 1 | 2024 | 2099 | 0.040 |
Why?
| | Acute Disease | 1 | 2019 | 373 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 326 | 0.040 |
Why?
| | Sex Factors | 1 | 2020 | 727 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 180 | 0.040 |
Why?
| | Solubility | 1 | 2017 | 79 | 0.030 |
Why?
| | Probiotics | 1 | 2017 | 24 | 0.030 |
Why?
| | Fluid Shifts | 1 | 2016 | 2 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 52 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2020 | 1132 | 0.030 |
Why?
| | Interleukin-8 | 1 | 2016 | 86 | 0.030 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2016 | 15 | 0.030 |
Why?
| | Child | 2 | 2020 | 7248 | 0.030 |
Why?
| | Ribonucleoprotein, U2 Small Nuclear | 1 | 2016 | 1 | 0.030 |
Why?
| | TATA-Binding Protein Associated Factors | 1 | 2016 | 2 | 0.030 |
Why?
| | Transcription Factor TFIID | 1 | 2016 | 5 | 0.030 |
Why?
| | Cyclin D2 | 1 | 2016 | 21 | 0.030 |
Why?
| | Physical Exertion | 1 | 2016 | 46 | 0.030 |
Why?
| | Electromyography | 1 | 2016 | 127 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2016 | 20 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2017 | 155 | 0.030 |
Why?
| | Histone Acetyltransferases | 1 | 2016 | 24 | 0.030 |
Why?
| | Anthropometry | 1 | 2016 | 101 | 0.030 |
Why?
| | Recovery of Function | 1 | 2017 | 199 | 0.030 |
Why?
| | Physical Examination | 1 | 2016 | 99 | 0.030 |
Why?
| | Exome | 1 | 2016 | 55 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 34 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 592 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 605 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 395 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2017 | 278 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 117 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 554 | 0.030 |
Why?
| | Risk Assessment | 1 | 2020 | 1327 | 0.030 |
Why?
| | Primary Health Care | 1 | 2019 | 376 | 0.030 |
Why?
| | Universities | 1 | 2016 | 175 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2016 | 119 | 0.030 |
Why?
| | Human Growth Hormone | 1 | 2015 | 50 | 0.030 |
Why?
| | Insulin, Long-Acting | 1 | 2015 | 2 | 0.030 |
Why?
| | International Agencies | 1 | 2015 | 14 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 229 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2016 | 117 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 979 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 451 | 0.030 |
Why?
| | Prevalence | 1 | 2018 | 1006 | 0.030 |
Why?
| | Child, Preschool | 1 | 2023 | 4076 | 0.030 |
Why?
| | Sample Size | 1 | 2014 | 44 | 0.030 |
Why?
| | Body Weight | 1 | 2016 | 523 | 0.030 |
Why?
| | Remission Induction | 1 | 2014 | 218 | 0.030 |
Why?
| | Genetic Markers | 1 | 2014 | 109 | 0.030 |
Why?
| | Societies, Medical | 1 | 2015 | 200 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2017 | 1567 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2016 | 1229 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 211 | 0.030 |
Why?
| | Inflammation | 1 | 2017 | 641 | 0.030 |
Why?
| | Apoptosis | 1 | 2018 | 1119 | 0.020 |
Why?
| | Research Design | 1 | 2014 | 359 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 857 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 1546 | 0.020 |
Why?
|
|
Church's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|